Astrotech Corporation (ASTC) Stock

Astrotech Corporation (ASTC) is a Technology stock trading at $7.70 (as of 2026-08-20), with a market capitalization of $13.54M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Astrotech Corporation is a science and technology development and commercialization company operating through three segments: Astrotech Technologies, 1st Detect, and AgLAB. It develops and licenses mass spectrometry technology and provides explosives and narcotics trace detection and breath analysis tools for use in security screening, and it also develops instruments for hemp and cannabis-related applications.

Understand Astrotech Corporation: how it makes money

Astrotech Corporation develops and commercializes science and technology, it makes money by owning and licensing AMS platform mass spectrometry technology (ATI) and by manufacturing explosives and narcotics trace detectors, TRACER 1000, for use at airports, secured facilities, and borders (1st Detect).

The profit model is structurally tied to commercialization of trace detection deployments (how widely TRACER 1000 is installed by location and country) and to ongoing monetization of AMS technology through ownership and licensing.

Business quality (Weak): Clear operating footprint metrics are provided for trace detection deployments, but segment revenue breakdowns are not available in the provided data, and the latest-quarter financials show revenue at 0.0B with a very large negative operating margin.

Bull case

  • Deployment footprint is measurable: The company tracks adoption through the number of trace detection system deployment locations and countries, which can indicate whether TRACER 1000 is getting installed across more sites and geographies.
  • Two commercialization paths: ATI monetizes AMS platform mass spectrometry technology through ownership and licensing, while 1st Detect manufactures trace detectors (TRACER 1000) positioned to replace existing explosives trace detectors.

Bear case

  • Latest-quarter profitability is weak: The provided latest-quarter operating margin is -1006.7%, indicating substantial operating losses.
  • No segment revenue details here: Without segment revenue information, it is harder to tell how much of performance comes from AMS licensing (ATI) versus TRACER 1000 manufacturing (1st Detect) versus AgLAB.
  • Reliance on deployment expansion as an operating driver: If TRACER 1000 deployments stall, that can directly pressure the operating driver the company reports, the number of deployment locations and deployment countries.
Valuation — source: SEC EDGAR (first-party)
Price$7.70
Market Cap$13.54M
Price / Book1.11
Price / Sales10.25
FCF Yield-264.5%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$1.00M
Net Margin-1385.0%
Return on Equity-115.9%
Current Ratio6.17
Revenue Growth (YoY)-35.8%
EPS Growth (YoY)3.2%
FCF Growth (YoY)8.5%
Financial Health — source: SEC EDGAR
Altman Z-Score-12.25 (distress)
Valuation vs Sector & Industry
Sector P/E (Technology)33.9
Industry P/E (Measuring & Control Equipment)51.8
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Insider Sells (12mo)2
Top Institutional HolderJ. Safra Sarasin Holding AG ($140049.00)
Institutional Holders Tracked10
Company
SectorTechnology
IndustryMeasuring & Control Equipment
CEOThomas Boone Pickens
Employees30
CountryUS
IPO Date1995-12-21

Related Companies (Business model: Medical Devices / Life Science Tools; 8 closest by market cap; US-domiciled)

  • Harvard Bioscience, Inc. (HBIO)
  • Quanterix Corporation (QTRX)
  • Nautilus Biotechnology, Inc. (NAUT)
  • Seer, Inc. (SEER)
  • Rapid Micro Biosystems, Inc. (RPID)
  • Precipio, Inc. (PRPO)
  • Birchtech Corp. (BCHT)
  • Bionano Genomics, Inc. (BNGO)
ASTC earnings history · ASTC institutional & insider holders · ASTC KPIs & operating metrics · ASTC financials · ASTC investor presentations & press releases · ASTC SEC filings · ASTC peers · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-08-20.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.